Clinical Evidence

Ubiquinol helps support optimal heart health

The role of Ubiquinol in restoring depleted levels of CoQ10 and improving ejection fraction

  • In case reports of 29 cardiac patients, those patients who switched to Ubiquinol (average of 334 mg/day) from CoQ10 (average 384 mg/day) for 18 months experienced an increase in average serum CoQ10 level from 2.9 µg/mL to 5.3 µg/mL (P<0.001)1

  • Average ejection fraction (EF), a measurement of the percentage of blood leaving (ejected from) the heart each time it contracts, improved from 40.9% to 47.8% (P<0.004)1

Higher Ubiquinol levels are shown to be associated with lower levels of blood markers of oxidative stress, including GGT, NT-proNBP, and CRP

GGT (gamma glutamyltransferase)

Ubiquinol reduces GGT in men

  • GGT is considered a marker of oxidative stress
  • Elevated serum GGT levels are associated with the development of certain cardiovascular conditions2-4

NT-proBNP

Higher serum levels of Ubiquinol, an antioxidant, are associated with lower serum NT-proBNP (N-terminal pro b-type natriuretic peptide) levels4

  • Elevated values of NT-proBNP are associated with certain cardiovascular conditions.
  • To read more about how Ubiquinol acts as an antioxidant, click here.

C-reactive protein

The relationship between CoQ10 and the serum level of c-reactive protein (CRP) was investigated in a large study population (n=1319; patient mean age of 48.0 ± 14.4 years)5

  • Ubiquinol status in plasma was significantly (P<0.001) correlated to the concentration of C-reactive protein (CRP); the greater the levels of oxidized CoQ10, the greater the levels of CRP
    • CRP in the blood may be a sign of a health condition
  • In a follow-up study with 53 healthy male patients, daily supplementation with 150 mg of Ubiquinol for 14 days significantly increased Ubiquinol plasma concentrations and decreased the CoQ10 redox status (% of oxidized form of CoQ10)

Additional evidence

  • As reported in a small study abstract, Ubiquinol was shown to improve endothelial function in cardiac patients with reduced ejection fraction5

    • Ubiquinol 400 mg/day for 3 months provided significant and clinically meaningful improvement in peripheral endothelial function in patients with HFrEF (heart failure with reduced ejection fraction); (n=14; average age 70)
References

  1. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. BioFactors. 2008;32(1-4):119-128.

  2. Dhingra R, Gona P, Wang TJ, et al.  Serum γ glutamyl transferase and risk of heart failure in the community.  Arterioscler Thromb Vasc Biol. 2010;30(9):1855–1860.

  3. Onur S, Niklowitz P, Jacobs G, et al.   Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans. BMC Res Notes. 2014;7:427.

  4. Onur S,  Niklowitz P,  Jacobs G,  et al. Association between serum level of ubiquinol and NT-proBNP, a marker for chronic heart failure, in healthy elderly subjects.  Biofactors. 2015;41(1):35-43.

  5. Passi S, Stancato A, Aleo E, et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. BioFactors. 2003;18(1-4):113-124.

  6. Kawashima C, Matsuzawa Y, Akiyama E, et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: A single center, randomized double-blind placebo-controlled cross-over study. Circulation. 2016;134 (suppl 1): Abstract 14946.